As per the agreement, both the companies will identify glycans, the complex carbohydrate component of glycoproteins, which is believed to play a role in health and disease.
Ezose’s GlycanMap technology platform will be used to focus on the identification of changes in glycan patterns on post-translationally modified proteins from human subjects.
Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells.
GlycanMap platform combines glycan enrichment with specialized MALDI-TOF mass spectrometry and custom bioinformatics to both structurally identify and quantitate glycans present in complex biological samples.
Various collaborative studies previously conducted with Merck will help in the advancement of the research deal.
Financial terms and other details have not been revealed